CALT · Calliditas Therapeutics
Acquired Company
Asahi Kasei completed the recommended public cash offer and became owner of 93.30% of all shares in Calliditas on September 2, 2024.
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing pharmaceutical products for treatments in orphan indications with an initial focus on kidney and liver diseases. The company is headquartered in Stockholm, Sweden.
KUNGSBRON 1, D5, STOCKHOLM, SWEDEN, 111 22, Stockholm, 111 22, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
1.097B
52 Wk Range
$0.00 - $0.00
Previous Close
$40.00
Open
$40.00
Volume
N/A
Day Range
$40.00 - $40.00
Enterprise Value
N/A
Cash
797.3M
Avg Qtr Burn
-7.043M
Insider Ownership
3.81%
Institutional Own.
0.32%
Qtr Updated
Jun 30th 2024